CVTX CV Therapeutics (MM)

-Study shows angina at one year associated with significantly higher incidence of depression- PALO ALTO, Calif., June 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) today announced that the Archives of Internal Medicine published results of a major study demonstrating that one in five patients studied experienced chest pain one year after a myocardial infarction (MI), or heart attack, and that this angina was associated with significantly elevated rates of depression among cardiac patients in the registry. PREMIER (Prospective Registry Evaluating Myocardial Infarction: Events and Recovery) was a "real-world" observational study in nearly 2,500 patients specifically designed to characterize patients' health status one year after a heart attack. Researchers found a significant (p